Each delivered dose contains:
Indacaterol 114 micrograms
Glycopyrronium 46 micrograms
Mometasone furoate 136 micrograms
Other ingredients include lactose monohydrate (contains milk proteins), magnesium stearate and capsule-shell ingredients detailed in the patient leaflet.
Enerzair Breezhaler Inhaler
Manufacturer: Novartis Pharmaceuticals UK Limited
Prescription required
Enerzair Breezhaler is a prescription-only maintenance treatment for asthma in adults whose asthma is not adequately controlled with a high-dose inhaled corticosteroid and a long-acting bronchodilator, and who have experienced at least one asthma exacerbation in the previous year.
It contains three active ingredients:
Indacaterol – a long-acting bronchodilator.
Glycopyrronium – a long-acting muscarinic antagonist that helps keep airways open.
Mometasone furoate – an inhaled corticosteroid that reduces airway inflammation.
Enerzair Breezhaler is taken regularly to help control asthma symptoms and is not intended for immediate relief of an asthma attack.
Supplied with 30 inhalation capsules and a Breezhaler inhaler device. This presentation does not include the optional electronic monitoring sensor.
Treatment requires appropriate clinical assessment and a valid prescription.
Each delivered dose contains:
Indacaterol 114 micrograms
Glycopyrronium 46 micrograms
Mometasone furoate 136 micrograms
Other ingredients include lactose monohydrate (contains milk proteins), magnesium stearate and capsule-shell ingredients detailed in the patient leaflet.